Amarin Corporation PLC Announces Notification Of Patent Allowances For U.S. Applications 13/685,281, And 13/685,291 Related To Triglyceride Lowering With A Mixture Of Omega-3 Free Fatty Acid (Including EPA And/Or DHA) In Both The MARINE And ANCHOR Patient
Published: Dec 02, 2013
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 2, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the United States Patent and Trademark Office (USPTO) has published notification of a Notices of Allowance for Amarin's U.S. Patent Applications Serial Numbers 13/685,281, and 13/685,291, each titled "Stable Pharmaceutical Composition and Methods of Using Same." The claims in these allowed applications cover methods of lowering triglycerides by administering a pharmaceutical composition comprised of a mixture of free fatty acids, including EPA and/or DHA to varying degrees, to patients with severe hypertriglyceridemia (the MARINE population) and in patients with hypertriglyceridemia on concomitant statin therapy (the ANCHOR population). A Notice of Allowance is issued after the USPTO makes a determination that a patent can be granted from an application. The issued patents would have terms that expire no earlier than in 2030.
Help employers find you! Check out all the jobs and post your resume.